Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Engineered human FcγRIIa fusion: A novel strategy to extend serum half-life of therapeutic proteins.

Biotechnology and bioengineering - 1 Aug 2020

Jo Migyeong, Ko Sanghwan, Hwang Bora, Min Sung-Won, Ha Ji Yeon, Lee Ji Chul, Jang Se-Eun, Jung Sang Taek

Abstract excerpt

The immunoglobulin G (IgG) molecule has a long circulating serum half-life (~3 weeks) through pH- dependent FcRn binding-mediated recycling. To hijack the intracellular trafficking and recycling mechanism of IgG as a way to extend serum persistence of non-antibody therapeutic proteins, we have evolved the ectodomain of a low-affinity human FcγRIIa for enhanced binding to the lower hinge and upper CH2 region of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Directed Molecular Evolution
Share to Gene Library

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Half-Life

Share to Immunoglobulin G

Share to Protein Binding

Share to Protein Engineering

Share to Receptors, IgG

Share to Recombinant Fusion Proteins

Source

Identifiers

PMID: 32369186
DOI: 10.1002/bit.27374

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Engineered human FcγRIIa fusion: A novel strategy to extend serum half-life of therapeutic proteins.PMID 32369186Read ↗

Extending human IgG half-life using structure-guided design.Semantic proximity Read ↗

An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies.Semantic proximity Read ↗

pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG RecyclingSemantic proximity Read ↗

Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector FunctionsSemantic proximity Read ↗

Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.Semantic proximity Read ↗

Engineered human IgG antibodies with longer serum half-lives in primates.Semantic proximity Read ↗

Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.Semantic proximity Read ↗

Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive ReviewSemantic proximity Read ↗

Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.Semantic proximity Read ↗

Fc Engineering: Tailored Synthetic Human IgG1-Fc Repertoire for High-Affinity Interaction with FcRn at pH 6.0.Semantic proximity Read ↗

Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.Semantic proximity Read ↗

A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-lifeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.